Arcus Biosciences, Inc.

NYSE:RCUS

Biotechnology

Healthcare
$15.76 -0.39%

-$0.09 today

Market cap
$2.27B
Beta
0.84
P/E (TTM)
-8.2
EPS (TTM)
-$2.94
52W Low $7.91High $28.72

Volume 1.97M

Average 1.17M

RCUS Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Arcus Biosciences, Inc.NYSE: RCUS

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow dips below year-ago levels

Q2 FY2026 financing cash flow of $16M fell 69.2% year over year, behind the +30.4% change in trailing-twelve-month financing cash flow. Sequentially, it rose 433.3% from the prior quarter. Over 3 fiscal years it compounded at +145.5% a year.

Context

  • Financing cash flow amounted to 197.6% of revenue in FY2025, up 90.2 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -69.2% toward the trailing-twelve-month pace of +30.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$16M+433.3% QoQ
Last fiscal yearDec 2025
$488M+76.2% YoY
LTMJun 2026
$313M+30.4% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-69.2%——
1 year+76.2%——
3-year CAGR+145.5%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
488M USD
Year-over-year change
+76.2%
4-year CAGR
+19.7%

Financing Cash Flow vs competitors

How RCUS compares with its peers on the latest reported figures

  • RCUS's LTM Jun 2026 financing cash flow of $313M is the 6th largest of the 9 companies compared; the peer median is $400.84M.
  • Its year-over-year change of +30.4% is the 5th highest of 9, against a peer median of +73.6%.
  • Financing cash flow amounts to 267.5% of revenue for RCUS, versus a peer median of 206.1%.
RCUS Competitors Peer median
Financing Cash Flow for RCUS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COGTCogent Biosciences, Inc.LTM Jun 2026$861.53M +1082.7%+75.1%—
VRDNViridian Therapeutics, Inc.LTM Jun 2026$748.24M +157.6%+9.8%1052.0%
OCULOcular Therapeutix, Inc.LTM Mar 2026$557.83M +3601.6%+628.3%1072.0%
DNLIDenali Therapeutics Inc.LTM Jun 2026$425.38M +1810.7%-15.2%11803.1%
IBRXImmunityBio, Inc.LTM Sep 2026$376.3M -16.8%+19.7%206.1%
RCUSArcus Biosciences, Inc.LTM Jun 2026$313M +30.4%+145.5%267.5%
BEAMBeam Therapeutics Inc.LTM Jun 2026$107.69M -77.5%+62.4%69.0%
LQDALiquidia CorporationLTM Jun 2026$40.85M -75.7%-2.8%9.1%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$9.14M -10.4%+54.6%13.8%
Peer median (excluding RCUS) $400.84M+73.6%+37.1%206.1%

Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income52.83M(267M)(307M)(283M)(353M)
Depreciation & Amortization4M6M8M10M10M
Deferred Income Tax00000
Stock-Based Compensation55M65M73M76M60M
Change in Working Capital(375.62M)623M(71M)22M(194M)
Accounts Receivables(17.05M)704M15M28M9M
Inventory00000
Accounts Payables(4.77M)8M(1M)3M24M
Other Working Capital(353.8M)(89M)(85M)(9M)(227M)
Other Non-Cash Items7.62M11M(9M)5M(5M)
Operating Cash Flow(256.17M)438M(306M)(170M)(482M)
Capital Expenditures(26.08M)(6M)(24M)(6M)(2M)
Acquisitions (Net)00000
Purchases of Investments(718.87M)(1.24B)(788M)(1.04B)(1.08B)
Sales of Investments741.08M837M1.01B965M1.14B
Other Investing Activities0(3M)000
Investing Cash Flow(3.87M)(413M)194M(84M)66M
Debt Repayment5M0047M49M
Common Stock Issued232.35M23M25M228M439M
Common Stock Repurchased(6K)0000
Dividends Paid00000
Other Financing Activities010M8M2M0
Financing Cash Flow237.34M33M33M277M488M
Effect of Forex Changes(2.8M)0000
Net Change in Cash(25.5M)58M(79M)23M72M
Free Cash Flow(282.25M)432M(330M)(176M)(484M)

Arcus Biosciences, Inc.

NYSE:RCUS

Intrinsic Alpha fair value

Locked

Current Price

$15.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.